Cervical Cancer Screening Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
Description
Cervical Cancer Screening Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
Cervical Cancer Screening Market is expected to be US$ 34.92 Billion by 2028 according to Renub Research. One of the most prevalent cancers in women worldwide is cervical cancer, and improving patient outcomes requires early screening and identification. The market for cervical cancer screening, which offers goods and services to identify and prevent cervical cancer, is expanding quickly. Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, with an average age of diagnosis of 50. There is an increasing need for reliable screening techniques due to the rising frequency of cervical cancer.
Increased public awareness, the aging population's expansion, and technological breakthroughs in screening have all been significant drivers of the cervical cancer screening industry. There is a higher demand for cervical cancer screening services because governments and nonprofit organizations aggressively promote screening programs and raise public awareness. In addition, given that older women have a higher chance of acquiring cervical cancer, the aging population is also anticipated to increase the demand for services for cervical cancer screening.
Cervical Cancer Screening Market is expected to grow at a CAGR of 4.57% from 2022 to 2028
There are invasive and non-invasive screening techniques available in the cervical cancer screening market. Colposcopy and biopsy are invasive procedures, although pap smears and HPV tests are not. Cervical cancer is detected using one of three screening methods. There are tests for Pap Smears, Human Papilloma Virus (HPV), and visual inspection with acetic acid (VIA). The most prevalent screening method for cervical cancer is the pap smear, which has been around for a while. HPV testing, on the other hand, is more accurate and can detect precancerous lesions early. Thus its use has recently expanded.
Given that HPV is virtually always the cause of cervical cancer, the HPV test has been approved as a second screening test for the disease (human papillomavirus). A high-risk HPV infection is more likely to result in cervix pre-cancers and cancers, as determined by the HPV test. It is possible to utilize the HPV test in conjunction with the Pap test or alone (primary HPV test) (called a co-test). As per this research report, Worldwide Cervical Cancer Screening Market was valued at US$ 26.7 Billion in 2022.
North America holds the highest share of Pap Smear and the HPV Market
The market for cervical cancer diagnostic tests worldwide was dominated by North America, Europe, Asia Pacific and Rest of the World. The American Cancer Society revealed both encouraging and alarming 2023 cancer statistics due to significant recent advancements in cancer prevention and screening in the United States (ACS). There will be 609,820 cancer deaths and 1,958,310 new cancer cases in the US in 2023, according to the American Cancer Society. The cervical cancer screening market in the US is a billion-dollar sector with a wide range of participants, including medical technology firms, insurance companies, diagnostic labs, and healthcare providers.
Cervical Cancer screening technology advancements have also significantly influenced the global cancer screening industry. The advent of new, more sensitive tests has boosted the accuracy of cervical cancer screening, resulting in earlier diagnosis and better patient outcomes. As a result, countries such as China, the United States, Canada, Japan, Korea, Singapore, India, Malaysia, Indonesia, Thailand, and the rest of the world are focusing on the early detection and prevention of cervical cancer illness. Other nations collaborating in this initiative include France, the United Kingdom, Germany, Italy, Spain, Sweden, Switzerland, Norway, the Netherlands, and the United States.
The cervical cancer screening market is likely to expand more in the next years, owing to rising public awareness, an older population, and technological developments. With the rising frequency of cervical cancer, women must be screened on a regular basis to detect and prevent the illness at an early stage. The cervical cancer screening market offers a variety of goods and services to assist women in obtaining the treatment they require to enhance their health outcomes.
Company Analysis
Companies are also investing in research and development to create new screening technologies that can detect cervical cancer at an even earlier stage. Some companies operate in the cervical cancer screening market, including Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation, and Cardinal Health.
The official release of a ""human papillomavirus (HPV) self-sampling solution"" in the areas accepting the CE mark will occur in June 2022, according to F. Hoffmann-La Roche Ltd., a multinational healthcare corporation based in Switzerland. The main benefit of this test kit is HPV screening, which can identify women at an increased risk of getting cervical cancer.
Supplier of in-vitro diagnostics SANSURE BIOTECH INC. announced in January 2022 that the China National Medical Products Administration had approved its ""HPV DNA Diagnostic Kit (HPV 13+2)"" (NMPA). The kit was created using cutting-edge magnetic bead technology and more than 13 different high-risk genotypes to guarantee that it can screen for cervical cancer.
According to Renub Research report ""Cervical Cancer Market, Patients Population Global Forecast by Tests (Pap Smear, HPV DNA, VIA), 20 Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Indonesia, Thailand and Rest of world) Company (Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation and Cardinal Health)” provides a complete analysis of Worldwide Cervical Cancer Screening Industry.""
Cervical Cancer Screening Market & Population – the report studies all 3 types of Test
1. Pap Smear Tests Market
2. HPV DNA Tests Market
3. VIA Tests Market
Cervical Cancer Countries Covered:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
10. United States
11. Canada
12. Japan
13. Korea
14. Singapore
15. Malaysia
16. India
17. China
18. Indonesia
19. Thailand
20. Rest of World
Companies have been covered from 3 viewpoints
• Overview
• Recent Development
• Sales
Company Analysis
1. Abbott Laboratories
2. Becton
3. Siemens AG
4. Quest Diagnostics
5. Roche
6. Cardinal Health
7. Hologic Corporation
Cervical Cancer Screening Market is expected to be US$ 34.92 Billion by 2028 according to Renub Research. One of the most prevalent cancers in women worldwide is cervical cancer, and improving patient outcomes requires early screening and identification. The market for cervical cancer screening, which offers goods and services to identify and prevent cervical cancer, is expanding quickly. Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, with an average age of diagnosis of 50. There is an increasing need for reliable screening techniques due to the rising frequency of cervical cancer.
Increased public awareness, the aging population's expansion, and technological breakthroughs in screening have all been significant drivers of the cervical cancer screening industry. There is a higher demand for cervical cancer screening services because governments and nonprofit organizations aggressively promote screening programs and raise public awareness. In addition, given that older women have a higher chance of acquiring cervical cancer, the aging population is also anticipated to increase the demand for services for cervical cancer screening.
Cervical Cancer Screening Market is expected to grow at a CAGR of 4.57% from 2022 to 2028
There are invasive and non-invasive screening techniques available in the cervical cancer screening market. Colposcopy and biopsy are invasive procedures, although pap smears and HPV tests are not. Cervical cancer is detected using one of three screening methods. There are tests for Pap Smears, Human Papilloma Virus (HPV), and visual inspection with acetic acid (VIA). The most prevalent screening method for cervical cancer is the pap smear, which has been around for a while. HPV testing, on the other hand, is more accurate and can detect precancerous lesions early. Thus its use has recently expanded.
Given that HPV is virtually always the cause of cervical cancer, the HPV test has been approved as a second screening test for the disease (human papillomavirus). A high-risk HPV infection is more likely to result in cervix pre-cancers and cancers, as determined by the HPV test. It is possible to utilize the HPV test in conjunction with the Pap test or alone (primary HPV test) (called a co-test). As per this research report, Worldwide Cervical Cancer Screening Market was valued at US$ 26.7 Billion in 2022.
North America holds the highest share of Pap Smear and the HPV Market
The market for cervical cancer diagnostic tests worldwide was dominated by North America, Europe, Asia Pacific and Rest of the World. The American Cancer Society revealed both encouraging and alarming 2023 cancer statistics due to significant recent advancements in cancer prevention and screening in the United States (ACS). There will be 609,820 cancer deaths and 1,958,310 new cancer cases in the US in 2023, according to the American Cancer Society. The cervical cancer screening market in the US is a billion-dollar sector with a wide range of participants, including medical technology firms, insurance companies, diagnostic labs, and healthcare providers.
Cervical Cancer screening technology advancements have also significantly influenced the global cancer screening industry. The advent of new, more sensitive tests has boosted the accuracy of cervical cancer screening, resulting in earlier diagnosis and better patient outcomes. As a result, countries such as China, the United States, Canada, Japan, Korea, Singapore, India, Malaysia, Indonesia, Thailand, and the rest of the world are focusing on the early detection and prevention of cervical cancer illness. Other nations collaborating in this initiative include France, the United Kingdom, Germany, Italy, Spain, Sweden, Switzerland, Norway, the Netherlands, and the United States.
The cervical cancer screening market is likely to expand more in the next years, owing to rising public awareness, an older population, and technological developments. With the rising frequency of cervical cancer, women must be screened on a regular basis to detect and prevent the illness at an early stage. The cervical cancer screening market offers a variety of goods and services to assist women in obtaining the treatment they require to enhance their health outcomes.
Company Analysis
Companies are also investing in research and development to create new screening technologies that can detect cervical cancer at an even earlier stage. Some companies operate in the cervical cancer screening market, including Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation, and Cardinal Health.
The official release of a ""human papillomavirus (HPV) self-sampling solution"" in the areas accepting the CE mark will occur in June 2022, according to F. Hoffmann-La Roche Ltd., a multinational healthcare corporation based in Switzerland. The main benefit of this test kit is HPV screening, which can identify women at an increased risk of getting cervical cancer.
Supplier of in-vitro diagnostics SANSURE BIOTECH INC. announced in January 2022 that the China National Medical Products Administration had approved its ""HPV DNA Diagnostic Kit (HPV 13+2)"" (NMPA). The kit was created using cutting-edge magnetic bead technology and more than 13 different high-risk genotypes to guarantee that it can screen for cervical cancer.
According to Renub Research report ""Cervical Cancer Market, Patients Population Global Forecast by Tests (Pap Smear, HPV DNA, VIA), 20 Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Indonesia, Thailand and Rest of world) Company (Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation and Cardinal Health)” provides a complete analysis of Worldwide Cervical Cancer Screening Industry.""
Cervical Cancer Screening Market & Population – the report studies all 3 types of Test
1. Pap Smear Tests Market
2. HPV DNA Tests Market
3. VIA Tests Market
Cervical Cancer Countries Covered:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
10. United States
11. Canada
12. Japan
13. Korea
14. Singapore
15. Malaysia
16. India
17. China
18. Indonesia
19. Thailand
20. Rest of World
Companies have been covered from 3 viewpoints
• Overview
• Recent Development
• Sales
Company Analysis
1. Abbott Laboratories
2. Becton
3. Siemens AG
4. Quest Diagnostics
5. Roche
6. Cardinal Health
7. Hologic Corporation
Table of Contents
600 Pages
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Global Cervical Cancer Test (Screening) Population
- 5.1 North America
- 5.2 Europe
- 5.3 Asia
- 5.4 Rest of World
- 6. Global Cervical Cancer Test (Screening) Market
- 6.1 Pap Smear Test (Screening)
- 6.2 HPV DNA Test (Screening)
- 7. Region – Global Cervical Cancer Test (Screening) Market Analysis
- 7.1 North America
- 7.2 Europe
- 7.3 Asia
- 7.4 Rest of World
- 8. Population Share – Global Cervical Cancer Test (Screening)
- 8.1 By Region
- 8.2 By Countries
- 9. Market Share – Global Cervical Cancer Test (Screening)
- 9.1 Region – Cervical Cancer Test (Screening)
- 9.2 Countries – Cervical Cancer Test (Screening)
- 9.3 Countries – Pap Smear Test (Screening)
- 9.4 Countries – HPV DNA Test (Screening)
- 9.5 Countries – VIA Test (Screening)
- 10. United Kingdom – Cervical Cancer Test Analysis
- 10.1 United Kingdom Cervical Cancer Test (Screening) Population
- 10.1.1 United Kingdom Pap Smear Test Population
- 10.1.2 United Kingdom HPV DNA Test Population
- 10.2 United Kingdom Cervical Cancer Test (Screening) Market
- 10.2.1 United Kingdom Pap Smear Test Market
- 10.2.2 United Kingdom HPV DNA Test Market
- 11. France – Cervical Cancer Test Analysis
- 11.1 France Cervical Cancer Test (Screening) Population
- 11.1.1 France Pap Smear Test Population
- 11.1.2 France HPV DNA Test Population
- 11.2 France Cervical Cancer Test (Screening) Market
- 11.2.1 France Pap Smear Test Market
- 11.2.2 France HPV DNA Test Market
- 12. Germany – Cervical Cancer Test Analysis
- 12.1 Germany Cervical Cancer Test (Screening) Population
- 12.1.1 Germany Pap Smear Test Population
- 12.1.2 Germany HPV DNA Test Population
- 12.2 Market – Cervical Cancer Test (Screening)
- 12.2.1 Germany Pap Smear Test Market
- 12.2.2 Germany HPV DNA Test Market
- 13. Italy – Cervical Cancer Test Analysis
- 13.1 Cervical Cancer Test (Screening) Population
- 13.1.1 Italy Pap Smear Test Population
- 13.1.2 Italy HPV DNA Test Population
- 13.2 Italy Cervical Cancer Test (Screening) Market
- 13.2.1 Italy Pap Smear Test Market
- 13.2.2 Italy HPV DNA Test Market
- 14. Spain – Cervical Cancer Test Analysis
- 14.1 Spain Cervical Cancer Test (Screening) Population
- 14.1.1 Spain Pap Smear Test Population
- 14.1.2 Spain HPV DNA Test Population
- 14.2 Spain Cervical Cancer Test (Screening) Market
- 14.2.1 Spain Pap Smear Test Market
- 14.2.3 Spain HPV DNA Test Market
- 15. Sweden – Cervical Cancer Test Analysis
- 15.1 Sweden Cervical Cancer Test (Screening) Population
- 15.1.1 Sweden Pap Smear Test Population
- 15.1.2 Sweden HPV DNA Test Population
- 15.2 Cervical Cancer Test (Screening) Market
- 15.2.1 Sweden Pap Smear Test Market
- 15.2.2 Sweden HPV DNA Test Market
- 16. Switzerland – Cervical Cancer Test Analysis
- 16.1 Switzerland Cervical Cancer Test (Screening) Population
- 16.1.1 Switzerland Pap Smear Test Population
- 16.1.2 Switzerland HPV DNA Test Population
- 16.2 Switzerland Cervical Cancer Test (Screening) Market
- 16.2.1 Switzerland Pap Smear Test Market
- 16.2.2 Switzerland HPV DNA Test Market
- 17. Norway – Cervical Cancer Test Analysis
- 17.1 Norway Cervical Cancer Test (Screening) Population
- 17.1.1 Norway Pap Smear Test Population
- 17.1.2 Norway HPV DNA Test Population
- 17.2 Norway Cervical Cancer Test (Screening) Market
- 17.2.1 Norway Pap Smear Test Market & Forecast
- 17.2.2 Norway HPV DNA Test Market
- 18. Netherlands – Cervical Cancer Test Analysis
- 18.1 Netherlands Cervical Cancer Test (Screening) Population
- 18.1.1 Netherlands Pap Smear Test Population
- 18.1.2 Netherlands HPV DNA Test Population
- 18.2 Netherlands Cervical Cancer Test (Screening) Market
- 18.2.1 Netherlands Pap Smear Test Market
- 18.2.2 Netherlands HPV DNA Test Market
- 19. United States – Cervical Cancer Test Analysis
- 19.1 United States Cervical Cancer Test (Screening) Population
- 19.1.1 United States Pap smear Test Population
- 19.1.2 United States HPV DNA Test Population
- 19.2 United States Cervical Cancer Test (Screening) Market
- 19.2.1 United States Pap Smear Test Market
- 19.2.2 United States HPV DNA Test Market
- 20. Canada – Cervical Cancer Test Analysis
- 20.1 Canada Cervical Cancer Test (Screening) Population
- 20.1.1 Canada Pap smear Test Population
- 20.1.2 Canada HPV DNA Test Population
- 20.2 Canada Cervical Cancer Test (Screening) Market
- 20.2.1 Canada Pap Smear Test Market
- 20.2.2 Canada HPV DNA Test Market
- 21. Japan – Cervical Cancer Test Analysis
- 21.1 Japan Cervical Cancer Test (Screening) Population
- 21.1.1 Japan Pap smear Test Population
- 21.1.2 Japan HPV DNA Test Population
- 21.2 Japan Cervical Cancer Test (Screening) Market
- 21.2.1 Japan Pap Smear Test Market
- 21.2.2 Japan HPV DNA Test Market
- 22. South Korea – Cervical Cancer Tests Analysis
- 22.1 South Korea - Cervical Cancer Test (Screening) Population
- 22.1.1 South Korea Pap Smear Test Population
- 22.1.2 Korea HPV DNA Test Population
- 22.2 Korea Cervical Cancer Test (Screening) Market
- 22.2.1 Korea Pap Smear Test Market
- 22.2.2 Korea HPV DNA Test Market
- 23. Singapore – Cervical Cancer Tests Analysis
- 23.1 Singapore - Cervical Cancer Test (Screening) Population
- 23.1.1 Singapore Pap Smear Test Population
- 23.1.2 Singapore HPV DNA Test Population
- 23.2 Singapore Cervical Cancer Test (Screening) Market
- 23.2.1 Singapore Pap Smear Test Market
- 23.2.2 Singapore HPV DNA Test Market
- 24. Malaysia – Cervical Cancer Test Analysis
- 24.1 Malaysia - Cervical Cancer Test (Screening) Population
- 24.1.1 Malaysia Pap Smear Test Population
- 24.1.2 Malaysia HPV DNA Test Population
- 24.2 Malaysia Cervical Cancer Test (Screening) Market
- 24.2.1 Malaysia Pap Smear Test Market
- 24.2.2 Malaysia HPV DNA Test Market
- 25. India – Cervical Cancer Test Analysis
- 25.1 India - Cervical Cancer Test (Screening) Population
- 25.1.1 India Pap Smear Test Population
- 25.1.2 India HPV DNA Test Population
- 25.1.3 India VIA Test Population
- 25.2 India Cervical Cancer Test (Screening) Market
- 25.2.1 India Pap Smear Test Market
- 25.2.2 India HPV DNA Test Market
- 25.2.3 India VIA Test Market
- 26. China – Cervical Cancer Test Analysis
- 26.1 China - Cervical Cancer Test (Screening) Population
- 26.1.1 China Pap Smear Test Population
- 26.1.2 China HPV DNA Test Population
- 26.1.3 China VIA Test Population
- 26.2 China - Cervical Cancer Test (Screening) Market
- 26.2.1 China Pap Smear Test Market
- 26.2.2 China HPV DNA Test Market
- 26.2.3 China VIA Test Market
- 27. Thailand – Cervical Cancer Test Analysis
- 27.1 Thailand - Cervical Cancer Test (Screening) Population
- 27.1.1 Thailand Pap Smear Test Population
- 27.1.2 Thailand VIA Test Population
- 27.2 Thailand Cervical Cancer Test (Screening) Market
- 27.2.1 Thailand Pap Smear Test Market
- 27.2.2 Thailand VIA Test Market
- 28. Indonesia – Cervical Cancer Test Analysis
- 28.1 Indonesia Cervical Cancer Test (Screening) Population
- 28.1.1 Indonesia Pap Smear Test Population
- 28.1.2 Indonesia HPV DNA Test Population
- 28.1.3 Indonesia VIA Test Population
- 28.1.4 Indonesia Pap Smear & VIA Test Population
- 28.2 Indonesia Cervical Cancer Test (Screening) Market
- 28.2.1 Indonesia Pap Smear Test Market
- 28.2.2 Indonesia HPV DNA Test Market
- 28.2.3 Indonesia VIA Test Market
- 28.2.4 Indonesia Pap smear & VIA Test Market
- 29. Rest of World – Cervical Cancer Test Analysis
- 29.1 Rest of World Cervical Cancer Test (Screening) Population
- 29.1.1 Rest of World Pap smear Test Population
- 29.1.2 Rest of World HPV DNA Test Population
- 29.2 Rest of World Cervical Cancer Test (Screening) Market
- 29.2.1 Rest of World Pap Smear Test Market
- 29.2.2 Rest of World HPV DNA Test Market
- 30. Company Analysis
- 30.1 Abbott laboratories
- 30.1.1 Overview
- 30.1.2 Recent Development
- 30.1.3 Revenue
- 30.2 Hologic Corporation
- 30.2.1 Overview
- 30.2.2 Recent Development
- 30.2.3 Revenue
- 30.3 Becton
- 30.3.1 Overview
- 30.3.2 Recent Development
- 30.3.3 Revenue
- 30.4 Siemens AG
- 30.4.1 Overview
- 30.4.2 Recent Development
- 30.4.3 Revenue
- 30.5 Roche Diagnostics
- 30.5.1 Overview
- 30.5.2 Recent Development
- 30.5.3 Revenue
- 30.6 Quest Diagnostics
- 30.6.1 Overview
- 30.6.2 Recent Development
- 30.6.3 Revenue
- 30.7 Cardinal Health
- 30.7.1 Overview
- 30.7.2 Recent Development
- 30.7.3 Revenue
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
